Zymeworks Ebitda vs Income Tax Expense Analysis
ZYME Stock | USD 13.10 0.04 0.31% |
Zymeworks Common financial indicator trend analysis is more than just analyzing Zymeworks Common Stock current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zymeworks Common Stock is a good investment. Please check the relationship between Zymeworks Common Ebitda and its Income Tax Expense accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Ebitda vs Income Tax Expense
Ebitda vs Income Tax Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zymeworks Common Stock Ebitda account and Income Tax Expense. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Zymeworks Common's Ebitda and Income Tax Expense is 0.55. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of Zymeworks Common Stock, assuming nothing else is changed. The correlation between historical values of Zymeworks Common's Ebitda and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Zymeworks Common Stock are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Ebitda i.e., Zymeworks Common's Ebitda and Income Tax Expense go up and down completely randomly.
Correlation Coefficient | 0.55 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Ebitda
Income Tax Expense
Most indicators from Zymeworks Common's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zymeworks Common Stock current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At present, Zymeworks Common's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 891.1 M, whereas Tax Provision is projected to grow to (539.6 K).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 12.9M | 3.6M | 4.1M | 5.8M | Depreciation And Amortization | 9.6M | 12.0M | 17.3M | 18.2M |
Zymeworks Common fundamental ratios Correlations
Click cells to compare fundamentals
Zymeworks Common Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zymeworks Common fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 368.2M | 538.4M | 389.1M | 648.7M | 580.9M | 337.6M | |
Other Current Liab | 45.6M | 76.7M | 65.4M | 61.7M | 39.8M | 36.8M | |
Total Current Liabilities | 82.6M | 85.7M | 71.9M | 95.6M | 55.8M | 51.5M | |
Total Stockholder Equity | (290.7M) | 409.9M | 249.1M | 493.0M | 464.8M | 488.0M | |
Other Liab | 34.3M | 37.0M | 37.3M | 35.4M | 40.7M | 22.5M | |
Net Tangible Assets | 227.6M | 375.0M | 215.6M | 472.2M | 543.0M | 570.2M | |
Property Plant And Equipment Net | 16.5M | 17.6M | 49.8M | 47.7M | 37.5M | 21.0M | |
Net Debt | (121.5M) | (233.4M) | (169.5M) | (372.8M) | (130.8M) | (137.4M) | |
Retained Earnings | (290.7M) | (471.3M) | (683.1M) | (558.8M) | (677.4M) | (643.6M) | |
Accounts Payable | 5.3M | 6.2M | 5.2M | 7.9M | 6.2M | 4.6M | |
Cash | 128.5M | 242.0M | 201.9M | 400.9M | 157.6M | 141.2M | |
Non Current Assets Total | 56.4M | 83.3M | 100.9M | 104.0M | 168.0M | 176.4M | |
Non Currrent Assets Other | 3.0M | 3.1M | 13.7M | 15.7M | 7.3M | 5.3M | |
Cash And Short Term Investments | 298.9M | 426.4M | 252.6M | 492.2M | 374.3M | 245.8M | |
Net Receivables | 2.2M | 15.3M | 15.6M | 33.4M | 19.5M | 10.9M | |
Common Stock Shares Outstanding | 38.0M | 50.4M | 52.1M | 65.2M | 68.9M | 42.3M | |
Liabilities And Stockholders Equity | (168.2M) | 538.4M | 389.1M | 648.7M | 580.9M | 609.9M | |
Other Current Assets | 10.7M | 26.9M | 40.0M | 19.1M | 19.1M | 13.6M | |
Other Stockholder Equity | (443.6M) | 163.6M | 197.7M | 151.6M | 142.3M | 149.4M | |
Total Liab | 122.5M | 128.5M | 140.0M | 155.8M | 116.1M | 92.7M | |
Total Current Assets | 311.8M | 455.1M | 288.2M | 544.7M | 412.9M | 266.6M | |
Short Term Debt | 1.3M | 2.7M | 1.3M | 6.6M | 30.1M | 31.6M | |
Intangible Assets | 23.7M | 22.9M | 21.5M | 26.4M | 25.3M | 19.8M | |
Common Stock | 450.2M | 724.2M | 741.1M | 906.8M | 1.0B | 510.8M | |
Property Plant Equipment | 16.5M | 12.2M | 22.8M | 47.7M | 54.8M | 57.5M | |
Short Long Term Debt Total | 6.9M | 8.6M | 32.3M | 28.1M | 26.7M | 28.1M | |
Current Deferred Revenue | 30.3M | 37.4M | 57.6M | 2.4M | 3.7M | 3.5M | |
Other Assets | 21.8M | 65.8M | 34.4M | 34.7M | 39.9M | 30.9M | |
Common Stock Total Equity | 320.1M | 450.2M | 724.2M | 741.1M | 852.3M | 894.9M | |
Short Term Investments | 170.5M | 184.3M | 50.7M | 91.3M | 216.8M | 116.2M | |
Non Current Liabilities Total | 40.0M | 42.8M | 68.2M | 60.1M | 60.3M | 45.8M | |
Capital Surpluse | 12.3M | 92.8M | 163.6M | 197.7M | 227.4M | 238.7M | |
Deferred Long Term Liab | 18.3M | 34.1M | 34.5M | 17.6M | 20.3M | 22.5M | |
Capital Lease Obligations | 6.9M | 8.6M | 41.2M | 28.1M | 26.7M | 15.4M | |
Non Current Liabilities Other | 978K | 8.7M | 33.7M | 3.0M | 1.6M | 1.5M | |
Net Invested Capital | 245.7M | 409.9M | 317.6M | 493.0M | 464.8M | 350.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.